Boston Scientific Corporation provided earnings guidance for the third quarter 2022 and full year. For the third quarter company expects net sales growth versus the prior year period, to be in a range of approximately 6% to 8% on a reported basis, and approximately 8% to 10% on an organic basis. The company estimates EPS on a GAAP basis in a range of $0.20 to $0.24 and adjusted EPS, excluding certain charges (credits), of $0.43 to $0.45.

For the full year company estimates net sales growth to be in a range of approximately 6.5% to 7.5% on a reported basis, and approximately 8% to 9% on an organic basis. The company now estimates EPS on a GAAP basis in a range of $0.69 to $0.76 and estimates adjusted EPS, excluding certain charges (credits), of $1.74 to $1.77.